skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum
Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum
Material Type:
Book 		Add to My Research

Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum

ISBN: 9783031335327 ;ISBN: 3031335333 ;ISBN: 9783031335334 ;ISBN: 3031335325 ;DOI: 10.1007/978-3-031-33533-4

Digital Resources/Online E-Resources

Citations Cited by
2
Activity quantification and dosimetry in radiopharmaceutical therapy with reference to 177Lutetium
Activity quantification and dosimetry in radiopharmaceutical therapy with reference to 177Lutetium
Material Type:
Article 		Add to My Research

Activity quantification and dosimetry in radiopharmaceutical therapy with reference to 177Lutetium

Frontiers in nuclear medicine, 2024-03, Vol.4 [Peer Reviewed Journal]

EISSN: 2673-8880 ;DOI: 10.3389/fnume.2024.1355912

Full text available

Citations Cited by
3
Philosophy of Cancer Theranostics
Philosophy of Cancer Theranostics
Material Type:
Article 		Add to My Research

Philosophy of Cancer Theranostics

Cancer biotherapy & radiopharmaceuticals, 2023-02, Vol.38 (1), p.1-7 [Peer Reviewed Journal]

2023, Mary Ann Liebert, Inc., publishers ;ISSN: 1084-9785 ;EISSN: 1557-8852 ;DOI: 10.1089/cbr.2022.0082 ;PMID: 36493375

Full text available

Citations Cited by
4
Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy
Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy
Material Type:
Article 		Add to My Research

Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy

The lancet oncology, 2020-09, Vol.21 (9), p.e431-e443 [Peer Reviewed Journal]

2020 Elsevier Ltd ;2020. Elsevier Ltd ;ISSN: 1470-2045 ;ISSN: 1474-5488 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(20)30323-5 ;PMID: 32888472

Full text available

Citations Cited by
5
Editorial: Targeted alpha particle therapy in oncology
Editorial: Targeted alpha particle therapy in oncology
Material Type:
Article 		Add to My Research

Editorial: Targeted alpha particle therapy in oncology

Frontiers in medicine, 2023-03, Vol.10, p.1165747-1165747 [Peer Reviewed Journal]

Copyright © 2023 Bruland, Larsen, Baum and Juzeniene. 2023 Bruland, Larsen, Baum and Juzeniene ;ISSN: 2296-858X ;EISSN: 2296-858X ;DOI: 10.3389/fmed.2023.1165747 ;PMID: 36960341

Full text available

Citations Cited by
6
Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists
Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists
Material Type:
Article 		Add to My Research

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

Frontiers in medicine, 2022-12, Vol.9, p.1034315-1034315 [Peer Reviewed Journal]

Copyright © 2022 Shi, Jakobsson, Greifenstein, Khong, Chen, Baum and Zhang. ;Copyright © 2022 Shi, Jakobsson, Greifenstein, Khong, Chen, Baum and Zhang. 2022 Shi, Jakobsson, Greifenstein, Khong, Chen, Baum and Zhang ;ISSN: 2296-858X ;EISSN: 2296-858X ;DOI: 10.3389/fmed.2022.1034315 ;PMID: 36569154

Full text available

Citations Cited by
7
Immuno-Imaging (PET/SPECT)-Quo Vadis?
Immuno-Imaging (PET/SPECT)-Quo Vadis?
Material Type:
Article 		Add to My Research

Immuno-Imaging (PET/SPECT)-Quo Vadis?

Molecules (Basel, Switzerland), 2022-05, Vol.27 (10), p.3354 [Peer Reviewed Journal]

2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 by the authors. 2022 ;ISSN: 1420-3049 ;EISSN: 1420-3049 ;DOI: 10.3390/molecules27103354 ;PMID: 35630835

Full text available

Citations Cited by
8
Long-term Nephrotoxicity after PRRT: Myth or Reality
Long-term Nephrotoxicity after PRRT: Myth or Reality
Material Type:
Article 		Add to My Research

Long-term Nephrotoxicity after PRRT: Myth or Reality

Theranostics, 2024, Vol.14 (2), p.451-459 [Peer Reviewed Journal]

The author(s). ;The author(s) 2024 ;ISSN: 1838-7640 ;EISSN: 1838-7640 ;DOI: 10.7150/thno.92487 ;PMID: 38169589

Full text available

Citations Cited by
9
Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs)
Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs)
Material Type:
Article 		Add to My Research

Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs)

Theranostics, 2024, Vol.14 (1), p.133-142 [Peer Reviewed Journal]

The author(s). ;2024. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The author(s) 2024 ;ISSN: 1838-7640 ;EISSN: 1838-7640 ;DOI: 10.7150/thno.88619 ;PMID: 38164147

Full text available

Citations Cited by
10
From Automated Synthesis to In Vivo Application in Multiple Types of Cancer—Clinical Results with [68Ga]Ga-DATA5m.SA.FAPi
From Automated Synthesis to In Vivo Application in Multiple Types of Cancer—Clinical Results with [68Ga]Ga-DATA5m.SA.FAPi
Material Type:
Article 		Add to My Research

From Automated Synthesis to In Vivo Application in Multiple Types of Cancer—Clinical Results with [68Ga]Ga-DATA5m.SA.FAPi

Pharmaceuticals (Basel, Switzerland), 2022-08, Vol.15 (8), p.1000 [Peer Reviewed Journal]

2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 by the authors. 2022 ;ISSN: 1424-8247 ;EISSN: 1424-8247 ;DOI: 10.3390/ph15081000 ;PMID: 36015148

Full text available

Citations Cited by
11
Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with 177Lu-PSMA and Combined 225Ac- and 177Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation
Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with 177Lu-PSMA and Combined 225Ac- and 177Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation
Material Type:
Article 		Add to My Research

Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with 177Lu-PSMA and Combined 225Ac- and 177Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation

Diagnostics (Basel), 2022-08, Vol.12 (8), p.1926 [Peer Reviewed Journal]

2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 by the authors. 2022 ;ISSN: 2075-4418 ;EISSN: 2075-4418 ;DOI: 10.3390/diagnostics12081926 ;PMID: 36010276

Full text available

Citations Cited by
12
The ICPO Foundation—on the way toward collaborative growth of theranostics
The ICPO Foundation—on the way toward collaborative growth of theranostics
Material Type:
Article 		Add to My Research

The ICPO Foundation—on the way toward collaborative growth of theranostics

European journal of nuclear medicine and molecular imaging, 2022, Vol.49 (2), p.443-444 [Peer Reviewed Journal]

The Author(s) 2022 ;The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1619-7070 ;EISSN: 1619-7089 ;DOI: 10.1007/s00259-021-05651-2 ;PMID: 34984500

Full text available

Citations Cited by
13
[68Ga]Ga-Pentixafor PET/CT imaging for in vivo CXCR4 receptor mapping in different lung cancer histologic sub-types: correlation with quantitative receptors’ density by immunochemistry techniques
[68Ga]Ga-Pentixafor PET/CT imaging for in vivo CXCR4 receptor mapping in different lung cancer histologic sub-types: correlation with quantitative receptors’ density by immunochemistry techniques
Material Type:
Article 		Add to My Research

[68Ga]Ga-Pentixafor PET/CT imaging for in vivo CXCR4 receptor mapping in different lung cancer histologic sub-types: correlation with quantitative receptors’ density by immunochemistry techniques

European journal of nuclear medicine and molecular imaging, 2023-03, Vol.50 (4), p.1216-1227 [Peer Reviewed Journal]

The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. ;2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. ;ISSN: 1619-7070 ;EISSN: 1619-7089 ;DOI: 10.1007/s00259-022-06059-2 ;PMID: 36482077

Full text available

Citations Cited by
14
Celebrating 80 years anniversary of radioiodine for use in thyroid cancer and perspectives for theranostics
Celebrating 80 years anniversary of radioiodine for use in thyroid cancer and perspectives for theranostics
Material Type:
Article 		Add to My Research

Celebrating 80 years anniversary of radioiodine for use in thyroid cancer and perspectives for theranostics

Annals of nuclear medicine, 2022-12, Vol.36 (12), p.1007-1009 [Peer Reviewed Journal]

The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine 2022 ;The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine 2022. ;ISSN: 0914-7187 ;EISSN: 1864-6433 ;DOI: 10.1007/s12149-022-01806-9

Full text available

Citations Cited by
15
Long axial field of view PET scanners: a road map to implementation and new possibilities
Long axial field of view PET scanners: a road map to implementation and new possibilities
Material Type:
Article 		Add to My Research

Long axial field of view PET scanners: a road map to implementation and new possibilities

European journal of nuclear medicine and molecular imaging, 2021-12, Vol.48 (13), p.4236-4245 [Peer Reviewed Journal]

The Author(s) 2021 ;2021. The Author(s). ;The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1619-7070 ;EISSN: 1619-7089 ;DOI: 10.1007/s00259-021-05461-6 ;PMID: 34136956

Full text available

Citations Cited by
16
Prediction of Cognitive Decline in Parkinson's Disease Using Clinical and DAT SPECT Imaging Features, and Hybrid Machine Learning Systems
Prediction of Cognitive Decline in Parkinson's Disease Using Clinical and DAT SPECT Imaging Features, and Hybrid Machine Learning Systems
Material Type:
Article 		Add to My Research

Prediction of Cognitive Decline in Parkinson's Disease Using Clinical and DAT SPECT Imaging Features, and Hybrid Machine Learning Systems

Diagnostics (Basel), 2023-05, Vol.13 (10), p.1691 [Peer Reviewed Journal]

COPYRIGHT 2023 MDPI AG ;2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2023 by the authors. 2023 ;ISSN: 2075-4418 ;EISSN: 2075-4418 ;DOI: 10.3390/diagnostics13101691 ;PMID: 37238175

Full text available

Citations Cited by
17
From Automated Synthesis to In Vivo Application in Multiple Types of Cancer—Clinical Results with [[sup.68]Ga]Ga-DATA[sup.5m].SA.FAPi
From Automated Synthesis to In Vivo Application in Multiple Types of Cancer—Clinical Results with [[sup.68]Ga]Ga-DATA[sup.5m].SA.FAPi
Material Type:
Article 		Add to My Research

From Automated Synthesis to In Vivo Application in Multiple Types of Cancer—Clinical Results with [[sup.68]Ga]Ga-DATA[sup.5m].SA.FAPi

Pharmaceuticals (Basel, Switzerland), 2022-08, Vol.15 (8) [Peer Reviewed Journal]

COPYRIGHT 2022 MDPI AG ;ISSN: 1424-8247 ;EISSN: 1424-8247 ;DOI: 10.3390/ph15081000

Full text available

Citations Cited by
18
India's growing nuclear medicine infrastructure and emergence of radiotheranotics in cancer care: Associated challenges and the opportunities to collaborate
India's growing nuclear medicine infrastructure and emergence of radiotheranotics in cancer care: Associated challenges and the opportunities to collaborate
Material Type:
Article 		Add to My Research

India's growing nuclear medicine infrastructure and emergence of radiotheranotics in cancer care: Associated challenges and the opportunities to collaborate

Indian journal of nuclear medicine, 2023-07, Vol.38 (3), p.201-207 [Peer Reviewed Journal]

COPYRIGHT 2023 Medknow Publications and Media Pvt. Ltd. ;2023. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 0972-3919 ;EISSN: 0974-0244 ;DOI: 10.4103/ijnm.ijnm_77_23

Full text available

Citations Cited by
19
Impressive Response to TANDEM Peptide Receptor Radionuclide Therapy with [sup.177]Lu/[sup.225]AcDOTA-LM3 Somatostatin Receptor Antagonist in a Patient with Therapy-Refractory, Rapidly Progressive Neuroendocrine Neoplasm of the Pancreas
Impressive Response to TANDEM Peptide Receptor Radionuclide Therapy with [sup.177]Lu/[sup.225]AcDOTA-LM3 Somatostatin Receptor Antagonist in a Patient with Therapy-Refractory, Rapidly Progressive Neuroendocrine Neoplasm of the Pancreas
Material Type:
Article 		Add to My Research

Impressive Response to TANDEM Peptide Receptor Radionuclide Therapy with [sup.177]Lu/[sup.225]AcDOTA-LM3 Somatostatin Receptor Antagonist in a Patient with Therapy-Refractory, Rapidly Progressive Neuroendocrine Neoplasm of the Pancreas

Diagnostics (Basel), 2024-05, Vol.14 (9) [Peer Reviewed Journal]

COPYRIGHT 2024 MDPI AG ;ISSN: 2075-4418 ;EISSN: 2075-4418 ;DOI: 10.3390/diagnostics14090907

Full text available

Citations Cited by

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (18)

Refine My Results

Creation Date 

From To
Refine
  1. Before 2020  (1)
  2. 2020 To 2020  (1)
  3. 2021 To 2021  (1)
  4. 2022 To 2023  (12)
  5. After 2023  (5)
  6. More options open sub menu

Resource Type 

  1. Articles  (18)
  2. Books  (1)
  3. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait